<DOC>
	<DOCNO>NCT00479128</DOCNO>
	<brief_summary>The goal clinical research study find high tolerable dose Gemzar® ( gemcitabine ) Adriamycin® ( doxorubicin ) give together Velcade® ( bortezomib ) patient urothelial cancer solid tumor .</brief_summary>
	<brief_title>Bortezomib With Gemcitabine/Doxorubicin Patients With Urothelial Cancer Other Solid Tumors</brief_title>
	<detailed_description>Gemcitabine doxorubicin design disrupt growth cancer cell , cause cancer cell start die . Bortezomib design enter cell interfere substance find inside cell responsible allow cell divide . This help kill tumor cell . If find eligible take part study , receive dos study drug base join study many people start . Two ( 2 ) participant enter dose level . Additional participant may add dose level well tolerate . The dos increase high tolerable dose find . You receive 3 study drug first day cycle . You receive gemcitabine 90 minute . Next receive doxorubicin 15-30 minute . Bortezomib give last 3-5 second . Every 14 day consider study `` cycle . '' While study , complete physical exam dose study drug . Blood ( 3 teaspoon ) draw check bone marrow kidney function week first month . The study doctor may decide draw blood often , side effect study drug . Your vital sign measure receive study drug 1 hour infusion . At end Cycle 3 , tumor status re-evaluated . You CT scan bone scan . Blood ( 2 tablespoon ) draw routine test . You take study disease get bad intolerable side effect occur . If stable disease , may continue receive therapy long physician feel benefiting . Once off-study , receive phone call every 6 month . You ask , status disease , treatment . This investigational study . Gemcitabine , doxorubicin , bortezomib FDA approve commercially available . Their use study consider investigational approved patient urothelial cancer . Up 80 patient take part study . All enrol MD Anderson .</detailed_description>
	<mesh_term>Urethral Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>1 . Voluntary write informed consent performance studyrelated procedure part normal medical care , understand consent may withdraw patient time without prejudice future medical care . 2 . Female patient either postmenopausal surgically sterilize willing use acceptable method birth control ( ie : hormonal contraceptive , intrauterine device , diaphragm spermicide , condom spermicide , abstinence ) duration study . Male subject agrees use acceptable method contraception duration study . 3 . All patient must : Have biopsy proven cancer ( i.e . solid tumor ) standard therapy available . If prior history ischemic heart disease exposure &gt; 200 mg/m^2 doxorubicin , patient must measure ejection fraction ( either MUGA , ECHO ventriculography ) least 45 % . Have preserve hepatic function show AST ( SGOT ) level &lt; 2 x upper limit normal INR ( patient NOT anticoagulant therapy ) &lt; 1.4 . Have normal serum creatinine ( &lt; =1.5 ) creatinine clearance ( measure Cockcroft Gault formula ) &gt; = 20 ml/min . 4 . All patient must measurable evaluable disease . In general , liver lung lesion least 1 cm , patient nodeonly disease lesion &gt; /= 1.5 cm great dimension . Patients disease confine bone may eligible measurable lytic defect present serum marker elevate ( &gt; 4 x ULN ) . The Study Chairman final arbiter question related measurability . Patients threedimensional mass pelvic sidewall fixation bladder examination anesthesia consider measurable disease . 5 . For second stage Phase I trial , patient must histologic demonstration metastatic locally unresectable transitional cell carcinoma urothelium . Minor component ( &lt; 50 % overall ) variant glandular squamous differentiation , evolution aggressive phenotype sarcomatoid small cell change acceptable . However , atypical histology dominant , treatment approach may appropriate , patient eligible . 6 . Zubrod performance status &lt; /= 2 . 7 . Patients must least one prior therapy eligible either first second stage ) Patients eligible number prior regimen regardless regimen contain ( i.e . prior Bortezomib combination gemcitabine adriamycin acceptable ) . 1 . Patient platelet count &lt; 100 x 10^9/L . 2 . Patient absolute neutrophil count &lt; 1.2 x 10^9/L . 3 . Patient &gt; /= Grade 2 peripheral neuropathy within 14 day enrollment . 4 . Patient total bilirubin &gt; 2.5 mg/dL . 5 . Patient hypersensitivity bortezomib , boron , mannitol , gemcitabine , doxorubicin . Gemcitabine skin rash control short course steroid allow . 6 . Female subject pregnant breastfeeding . 7 . Confirmation subject pregnant must establish negative serum betahuman chorionic gonadotropin ( betahCG ) pregnancy test ( Unless reasonable certainty betahCG come tumor ) . Pregnancy test require postmenopausal surgically sterilize woman . 8 . Patient receive investigational drug 14 day enrollment . 9 . Serious medical psychiatric illness likely interfere participation clinical study . 10 . Patients significant atherosclerotic disease , define : ) Myocardial infarction within 6 month prior enrollment New York Heart Association ( NYHA ) Class III IV heart failure , uncontrolled angina , severe uncontrolled ventricular arrhythmia , ECG evidence acute ischemia active conduction system abnormality . Any prior ECG abnormality Screening document investigator medically relevant . b ) Symptomatic congestive heart failure . c ) Claudication limit activity ) History cerebrovascular event within last year ( include TIA ) . 11 . Patient uncontrolled brain metastasis central nervous system disease . 12 . Patients active , likely become active second malignancy . 13 . Patients must least 6 week pelvic irradiation , must 10 % bone marrow irradiate .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Solid Tumor</keyword>
	<keyword>Bladder Cancer</keyword>
	<keyword>Ureteral Cancer</keyword>
	<keyword>Urothelial Cancer</keyword>
	<keyword>Urethral Cancer</keyword>
	<keyword>Renal Pelvis Tumor</keyword>
	<keyword>Bortezomib</keyword>
	<keyword>Gemcitabine</keyword>
	<keyword>Doxorubicin</keyword>
	<keyword>Gemzar</keyword>
	<keyword>Adriamycin</keyword>
	<keyword>Velcade</keyword>
	<keyword>LDP-341</keyword>
	<keyword>MLN341</keyword>
	<keyword>PS-341</keyword>
	<keyword>Gemcitabine Hydrochloride</keyword>
	<keyword>AD</keyword>
	<keyword>Hydroxydaunomycin hydrochloride</keyword>
</DOC>